There are currently 1307 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Piedmont Cancer Institute, Atlanta, Georgia +1 locations
Conditions: Breast Cancer
Register for Updates
DECIDE: Dyads and Families
NCT05139290
Recruiting
The purpose of this study is to design and test a decision-making program that is tailored to support adult daughters making healthcare decisions for their parents who are living with memory loss to improve the quality of life of African American families. There are two phases of this research study. The first phase will collect information by surveys and/or interviews. The surveys and interviews will ask questions about demographics (e.g., age, race/ethnicity), culture, health, family dynamics... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Emory Healthcare Integrated Memory Care Clinic, Atlanta, Georgia +2 locations
Conditions: Dementia, Alzheimer Disease, Caregiver Burden
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: Neoplasms
Register for Updates
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142
Recruiting
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Clear Cell Renal Cell Carcinoma
Register for Updates
Clarithromycin Mechanisms in Hypersomnia Syndromes
NCT04026958
Recruiting
The purpose of this study is to evaluate a medication called clarithromycin for treating sleepiness in narcolepsy and idiopathic hypersomnia. Studies have shown that clarithromycin can reduce sleepiness, but researchers do not know how clarithromycin does this. This study will look at brain activity (on magnetic resonance imaging \[MRI\]), inflammation, bacteria living in the gut, and cerebrospinal fluid, to better understand how clarithromycin can reduce sleepiness. This study will recruit 92 p... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/18/2024
Locations: Emory Sleep Center, Atlanta, Georgia
Conditions: Narcolepsy Without Cataplexy, Idiopathic Hypersomnia, Narcolepsy With Cataplexy
Register for Updates
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT02977468
Recruiting
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of MK-3475 prior to lumpectomy.
Gender:
FEMALE
Ages:
Between 21 years and 80 years
Trial Updated:
06/17/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Triple Negative Breast Cancer
Register for Updates
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
NCT02447874
Recruiting
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
Gender:
ALL
Ages:
Between 7 years and 21 years
Trial Updated:
06/12/2024
Locations: Children's Healthcare fo Atlanta at Hughes Spalding, Atlanta, Georgia +1 locations
Conditions: Sickle Cell Disease
Register for Updates
Biphasic Effects of Acute Alcohol Intoxication on Bystander Intervention
NCT05701865
Recruiting
The goal of this experimental study is to examine the effect of alcohol, gender, and bystander attitudes on bystander barriers and sexual violence intervention among young adult men and women (age 21-20). The main questions it aims to answer are: * Does alcohol intoxication and gender influence bystander barriers and sexual violence intervention? * Does alcohol intoxication have a greater impact on bystander barriers and sexual violence intervention among men, compared to women? * Does alcohol... Read More
Gender:
ALL
Ages:
Between 21 years and 30 years
Trial Updated:
06/10/2024
Locations: Georgia State University, Atlanta, Georgia
Conditions: Alcohol Intoxication
Register for Updates
Natural Progesterone for the Treatment of Recurrent Glioblastoma
NCT05091866
Recruiting
This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Gliosarcoma, Recurrent Glioblastoma
Register for Updates
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
NCT04848519
Recruiting
This research study is an open label study designed to evaluate the safety and translational correlative changes of the combination of propranolol hydrochloride and immune checkpoint inhibitors (ICI) in subjects with urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Register for Updates
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
NCT05756569
Recruiting
This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. Enfortumab attaches to a protein... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Grady Health System, Atlanta, Georgia +3 locations
Conditions: Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma
Register for Updates
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
NCT03926520
Recruiting
This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/30/2024
Locations: Emory Healthcare, Atlanta, Georgia
Conditions: Alzheimer Dementia, Agitation,Psychomotor
Register for Updates